All In Biotech

Drug Trial Radar · NCT05583344

Phase 2b Study of GSK4532990 in Adults With NASH

17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Jan 2, 2023

Primary completion

Jan 31, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.

Conditions

  • Nonalcoholic Fatty Liver Disease
  • Non-alcoholic Fatty Liver Disease

Interventions

  • GSK4532990Drug

    GSK4532990 will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving ≥ 1 Stage Improvement in Histological Fibrosis with no Worsening of NASH - F3 CohortTime frame: At Week 52
  2. Percentage of Participants Achieving NASH Resolution with no Worsening of Fibrosis - F3 CohortTime frame: At Week 52

Locations

171 sites in 17 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Homewood, Alabama

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    North Little Rock, Arkansas

  • GSK Investigational Site

    Huntington Park, California

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Orange, California

  • GSK Investigational Site

    Poway, California

  • GSK Investigational Site

    Rialto, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Santa Ana, California

  • GSK Investigational Site

    Van Nuys, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Bradenton, Florida

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Hallandale, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Homestead, Florida

  • GSK Investigational Site

    Jupiter, Florida

  • GSK Investigational Site

    Lakewood Rch, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Athens, Georgia

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Marietta, Georgia

  • GSK Investigational Site

    Snellville, Georgia

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    South Bend, Indiana

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Bastrop, Louisiana

  • GSK Investigational Site

    Marrero, Louisiana

  • GSK Investigational Site

    Metairie, Louisiana

Showing 40 of 171 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.